STOCK TITAN
  1. Home
  2. Sec-filings
  3. CNTB
  4. [Form 4] Connect Biopharma Holdings Ltd Insider Trading Activity

Connect Biopharma (NASDAQ: CNTB) director receives 6,718-share award as 2026 board compensation

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Connect Biopharma Holdings Ltd director Jean I. Liu received a stock grant as board compensation. She acquired 6,718 ordinary shares at no cash cost, issued as fully vested shares in lieu of cash retainers for her 2026 annual board service during the second quarter of 2026.

After this award, she directly holds 11,779 ordinary shares. The number of shares granted was calculated by dividing the applicable equity value by the average closing price of the company’s ordinary shares for the 30 days preceding June 30, 2026, then rounding down to the nearest whole share.

Positive

  • None.

Negative

  • None.

Insights

Routine equity grant to director in lieu of cash fees.

Director Jean I. Liu received 6,718 fully vested ordinary shares of Connect Biopharma Holdings Ltd as compensation under the Non-Employee Director Compensation Program. This replaced cash retainers for 2026 board service in the second quarter.

The grant carries a transaction code A, indicating a grant or award rather than an open-market purchase. Following the award, Liu holds 11,779 ordinary shares directly. This looks like a standard, programmatic equity-for-fees arrangement, not a discretionary buy or sell, so the signal for investors is routine and neutral.

Insider LIU JEAN I
Role Director
Type Security Shares Price Value
Grant/Award Ordinary Shares 6,718 $0.00 $0.00
Holdings After Transaction: Ordinary Shares — 11,779 shares (Direct)
Footnotes (1)
  1. F1. In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Ms. Liu elected to receive fully vested shares in lieu of cash compensation for her 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Ms. Liu for her service as a director during the second quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares for the 30 days preceding June 30, 2026, rounded down to the nearest whole share.
Shares granted 6,718 shares Fully vested ordinary shares granted as Q2 2026 board retainers
Price per share $0.0000 per share Reported transaction price for the stock award
Shares held after 11,779 shares Jean I. Liu’s direct holdings following the grant
Compensation basis period 30 trading days Average closing price over 30 days preceding June 30, 2026
Non-Employee Director Compensation Program financial
"In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Ms. Liu elected to receive fully vested shares…"
fully vested shares financial
"Ms. Liu elected to receive fully vested shares in lieu of cash compensation for her 2026 annual board retainers."
in lieu of cash compensation financial
"Ms. Liu elected to receive fully vested shares in lieu of cash compensation for her 2026 annual board retainers."
average closing price financial
"calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares for the 30 days preceding June 30, 2026"
The average closing price is the arithmetic mean of a security’s end-of-day prices over a chosen period, found by adding each day’s closing price and dividing by the number of days. It smooths out daily ups and downs to show a typical market value—like averaging daily temperatures to understand a month’s climate—and helps investors spot trends, judge whether a stock is generally rising or falling, and make clearer buy or sell decisions.

FAQ

What did CNTB director Jean I. Liu report in this Form 4 filing?
Jean I. Liu reported receiving 6,718 ordinary shares of Connect Biopharma Holdings Ltd as a stock award. These fully vested shares were issued under the company’s Non-Employee Director Compensation Program instead of paying her 2026 annual board retainers in cash for second-quarter service.

How many CNTB shares does Jean I. Liu hold after this reported transaction?
After the reported transaction, Jean I. Liu directly holds 11,779 ordinary shares of Connect Biopharma Holdings Ltd. This total reflects the addition of 6,718 fully vested shares granted as director compensation in lieu of cash retainers for her 2026 board service during the second quarter.

Was the CNTB Form 4 transaction a market purchase or sale by Jean I. Liu?
The Form 4 transaction was not a market purchase or sale. It is coded “A” for a grant, award, or other acquisition, reflecting fully vested shares granted as non-employee director compensation instead of cash fees, rather than Liu buying or selling shares in the open market.

How was the number of CNTB shares in Jean I. Liu’s grant determined?
The number of shares was determined by dividing the applicable equity value by the average closing price of Connect Biopharma’s ordinary shares for the 30 days preceding June 30, 2026. The resulting figure was then rounded down to the nearest whole share under the director compensation program.

What period of service does Jean I. Liu’s CNTB share grant cover?
The grant relates to Jean I. Liu’s service as a director during the second quarter of 2026. Under the Non-Employee Director Compensation Program, she elected to receive fully vested ordinary shares instead of cash board retainers tied to her 2026 annual board service for that quarter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LIU JEAN I
(Last)(First)(Middle)
3580 CARMEL MOUNTAIN ROAD, SUITE 200
(Street)
SAN DIEGO CALIFORNIA 92130
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Connect Biopharma Holdings Ltd [ CNTB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares06/30/2026A6,718(1)A$011,779D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Ms. Liu elected to receive fully vested shares in lieu of cash compensation for her 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Ms. Liu for her service as a director during the second quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares for the 30 days preceding June 30, 2026, rounded down to the nearest whole share.
Remarks:
/s/ Lisa Peraza attorney-in-fact for Jean I Liu07/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR